ALVO

NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Dollar change -0.02
Percentage change -0.22	%

Peers: ABBV PFE MRK LLY AMGN BIIB VRTX GILD REGN BMY

| Held by: IBB PRFZ IBBQ BIB GLCR STXK RFLR

Scroll to Statements

Index	-	P/E	27.05	EPS (ttm)	0.34	Insider Own	63.90%	Shs Outstand	301.81M	Perf Week	-0.11%
Market Cap	2.75B	Forward P/E	17.79	EPS next Y	0.51	Insider Trans	0.00%	Shs Float	108.97M	Perf Month	-18.13%
Enterprise Value	3.94B	PEG	-	EPS next Q	-0.00	Inst Own	5.64%	Short Float	1.28%	Perf Quarter	-4.50%
Income	96.55M	P/S	4.89	EPS this Y	124.17%	Inst Trans	11.79%	Short Ratio	6.80	Perf Half Y	-27.39%
Sales	562.74M	P/B	-	EPS next Y	143.71%	ROA	8.37%	Short Interest	1.39M	Perf YTD	-31.07%
Book/sh	-1.00	P/C	71.42	EPS next 5Y	-	ROE	-	52W High	13.70 -33.43%	Perf Year	-24.13%
Cash/sh	0.13	P/FCF	-	EPS past 3/5Y	- -30.68%	ROIC	10.96%	52W Low	7.35 24.08%	Perf 3Y	1.33%
Dividend Est.	-	EV/EBITDA	29.01	Sales past 3/5Y	- -	Gross Margin	58.99%	Volatility	2.97% 4.24%	Perf 5Y	-
Dividend TTM	-	EV/Sales	7.00	EPS Y/Y TTM	118.30%	Oper. Margin	18.39%	ATR (14)	0.42	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	1.19	Sales Y/Y TTM	539.47%	Profit Margin	17.16%	RSI (14)	40.52	Recom	1.50
Dividend Gr. 3/5Y	- -	Current Ratio	1.73	EPS Q/Q	144.33%	SMA20	-7.61%	Beta	0.12	Target Price	18.88
Payout	-	Debt/Eq	-	Sales Q/Q	784.21%	SMA50	-4.58%	Rel Volume	1.17	Prev Close	9.14
Employees	1032	LT Debt/Eq	-	Earnings	May 07 AMC	SMA200	-19.08%	Avg Volume	204.39K	Price	9.12
IPO	Nov 09, 2020	Option/Short	No / Yes	EPS/Sales Surpr.	408.91% 39.76%	Trades		Volume	239,314	Change	-0.22%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-14-25	Initiated	UBS	Buy	$18
Jan-29-24	Upgrade	Barclays	Equal Weight → Overweight	$10 → $17
Oct-20-23	Upgrade	Citigroup	Sell → Neutral	$5 → $10
Sep-21-23	Initiated	Barclays	Equal Weight	$10
Sep-07-22	Initiated	Morgan Stanley	Equal-Weight	$10
Sep-06-22	Downgrade	Citigroup	Buy → Sell	$12 → $5
Jul-26-22	Initiated	Citigroup	Buy	$12

Jun-26-25 10:25AM	Alvotech, Kashiv, Advanz announce study of AVT23 met primary endpoint (TipRanks)
04:15AM	Alvotech's Lenders Lower Interest on Senior Secured Term Loan Facility (GlobeNewswire)
Jun-25-25 04:45PM	Main Results of 2025 Annual and Extraordinary General Meeting (GlobeNewswire)
04:00AM	Positive Top Line Results from Confirmatory Efficacy Study for Proposed Biosimilar to Xolair (omalizumab) (GlobeNewswire)
Jun-24-25 09:05AM	Alvotech (ALVO): A Bull Case Theory (Insider Monkey)
04:00AM	Loading…
Jun-23-25 04:00AM	European Medicines Agency Recommends Market Approval of AVT06, Alvotech's Proposed Biosimilar to Eylea (aflibercept) (GlobeNewswire)
Jun-11-25 04:20PM	Alvotech's Private Placement Completed with Delivery of SDRs and Shares to Investors (GlobeNewswire)
Jun-09-25 09:55AM	Wall Street Analysts Think Alvotech (ALVO) Could Surge 72.61%: Read This Before Placing a Bet (Zacks)
Jun-06-25 08:30AM	Alvotech Participates in the Goldman Sachs Global Healthcare Conference in Miami (GlobeNewswire)
08:30AM	Alvotech Meets Investors and Presents at the Goldman Sachs Global Healthcare Conference in Miami (GlobeNewswire)
08:18AM	Alvotech and Dr. Reddy's partner for Keytruda biosimilar (Pharmaceutical Business Review)
Jun-05-25 11:28AM	RDY & ALVO Ink Collaboration Deal for Merck's Keytruda Biosimilar (Zacks)
07:00AM	Alvotech and Dr. Reddys Enter into Collaboration to Co-Develop Biosimilar Candidate to Keytruda (pembrolizumab) (Business Wire)
Jun-04-25 10:29PM	Alvotech has carried out a private placement of 7,500,000 SDRs and ordinary shares at a price of SEK 100.00 per SDR and ISK 1320.83 per ordinary share, raising gross proceeds of SEK 750 million (GlobeNewswire) -5.41%
11:32AM	Alvotech intends to carry out a private placement of approximately 7.5 million SDRs and ordinary shares (GlobeNewswire)
07:45AM	Loading…
07:45AM	Alvotech Completes Acquisition of Xbrane R&D Organization and biosimilar candidate to Cimzia (GlobeNewswire)
Jun-02-25 09:15AM	Alvotech Meets Investors and Presents at the Jefferies Global Healthcare Conference 2025 in New York, NY (GlobeNewswire)
May-28-25 06:15AM	Alvotech and Advanz Pharma Extend Strategic Partnership to Commercialize Three Additional Biosimilars in Europe (GlobeNewswire)
May-26-25 02:06PM	Alvotech Annual General Meeting to be held June 25, 2025 (GlobeNewswire)
May-23-25 12:11PM	Transactions of Managers and Closely Associated Persons (GlobeNewswire)
May-19-25 03:15AM	Alvotech Appoints DNB Carnegie as Liquidity Provider on Nasdaq Stockholm (GlobeNewswire)
02:30AM	Trading in Alvotech's Shares on Nasdaq Stockholm Commences Today (GlobeNewswire)
May-16-25 01:52PM	Alvotech Announces the Outcome of the Offering in Connection with the Company's Listing on Nasdaq Stockholm (GlobeNewswire)
10:28AM	Transactions of Managers and Closely Associated Persons (GlobeNewswire)
May-13-25 04:05AM	Transactions of Managers and Closely Associated Persons (GlobeNewswire)
May-12-25 09:20AM	RDY Q4 Earnings Beat Estimates, Generics Revenues Rise Y/Y, Stock Up (Zacks) +5.89%
May-09-25 08:45AM	Is Alvotech (ALVO) The Best Stock That Will Bounce Back? (Insider Monkey)
08:00AM	Alvotech Meets Investors and Participates in Fireside Chat At the BofA Securities Healthcare Conference 2025 in Las Vegas, Nevada (GlobeNewswire)
07:17AM	Transactions of Managers and Closely Associated Persons (GlobeNewswire)
May-08-25 02:30AM	Alvotech Publishes Prospectus in Connection with its Listing on Nasdaq Stockholm (GlobeNewswire) +18.14%
04:45PM	Loading…
May-07-25 04:45PM	Alvotech Reports Results for the First Quarter of 2025 and Provides Business Update (GlobeNewswire)
06:20AM	Alvotech sees minimal impact on 2025 product revenues from tariffs (Seeking Alpha)
05:00AM	Potential U.S. Tariffs on Pharmaceuticals Expected to Have Minimal Impact on Alvotech's Product Revenues in 2025 (GlobeNewswire)
May-05-25 07:00AM	Teva and Alvotech Announce FDA Approval of Interchangeability for SELARSDI (ustekinumab-aekn) with Stelara (ustekinumab) (GlobeNewswire)
May-02-25 08:30AM	Alvotech Announces Webcast of First Quarter 2025 Financial Results on May 8, 2025, at 8:00 am EDT (GlobeNewswire)
08:30AM	Alvotech Announces Webcast of First Quarter 2025 Financial Results on May 8, 2025, at 8:00 am EDT (14:00 CET) (GlobeNewswire)
Apr-30-25 04:39PM	Alvotech: Potential Victim Of Pharma Tariff Threats (Rating Downgrade) (Seeking Alpha)
Apr-27-25 11:40PM	Why AbbVie's Stock Is A Strong Buy After Q1 2025 Results (Seeking Alpha)
Apr-25-25 06:33AM	New Strong Sell Stocks for April 25th (Zacks) -5.14%
Apr-24-25 07:46AM	Johnson & Johnson Just Proved The Bears Wrong Again (Seeking Alpha)
Apr-17-25 05:27AM	New Strong Sell Stocks for April 17th (Zacks)
Mar-31-25 09:30AM	RDY & Bio-Thera Ink Deal for JNJ's Stelara/Simponi Biosimilar (Zacks)
Mar-28-25 05:01PM	This Is a Test From GlobeNewswire (GlobeNewswire) -7.82%
Mar-27-25 12:09PM	Alvotech (ALVO) Q4 2024 Earnings Call Transcript (SeekingAlpha) -10.30%
04:30AM	Alvotech Appoints Dr. Balaji V. Prasad as Chief Strategy Officer (GlobeNewswire)
Mar-26-25 06:36PM	Alvotech Reports Record Results for 2024 and Provides Business Update (GlobeNewswire)
04:30AM	UK Medicines and Healthcare Products Regulatory Agency Confirms Acceptance of Marketing Authorization Application for Proposed Biosimilar to Xolair (omalizumab) (GlobeNewswire)
Mar-20-25 04:09AM	Alvotech acquires Xbrane's R&D operations in Sweden and biosimilar candidate XB003 (SeekingAlpha)
03:00AM	Alvotech Acquires Xbrane's R&D Operations in Sweden and Further Affirms its Global Leadership Position in Biosimilars Development and Production (GlobeNewswire)
Mar-19-25 11:13AM	FDA Accepts RDY & ALVO's Prolia & Xgeva Biosimilar BLA for Review (Zacks)
07:45AM	Liquidia Technologies, Inc. (LQDA) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
Mar-18-25 08:35AM	Alvotech and Dr. Reddys Announce FDA Acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia and Xgeva (Business Wire)
Mar-07-25 09:00AM	Alvotech Meeting Investors and Participates in Fireside Chat At Barclays 27th Global Healthcare Conference in Miami, Florida (GlobeNewswire)
Feb-24-25 08:00AM	Alvotech to Report Full Year Financial Results for 2024 on March 26, 2025, and Hosts Conference Call on March 27, 2025, at 8:00 am ET (GlobeNewswire)
Feb-21-25 06:00AM	Teva and Alvotech Announce SELARSDI (ustekinumab-aekn) Injection Now Available in the U.S. (GlobeNewswire)
Feb-18-25 11:27AM	FDA To Review Teva and Alvotech Drug That Could Compete With Regeneron's Eylea (Investopedia)
06:00AM	Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed Biosimilar to Eylea (aflibercept) (GlobeNewswire)
Jan-27-25 06:00AM	Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Applications for AVT05, a Proposed Biosimilar to Simponi and Simponi Aria (golimumab) (GlobeNewswire)
Dec-23-24 04:00AM	Alvotech Added to Nasdaq Biotech Index Effective Monday December 23, 2024 (GlobeNewswire) +5.12%
Nov-15-24 02:07AM	Alvotech (ALVO) Q3 2024 Earnings Call Highlights: Record Revenue Growth and Strategic Advancements (GuruFocus.com)
Nov-13-24 04:05PM	Alvotech Reports Financial Results for the First Nine Months of 2024 (GlobeNewswire)
Nov-07-24 08:00AM	Alvotech Attending Citi's Global Healthcare Conference on December 4, 2024, and Evercore's HealthCONx Conference on December 5, 2024 (GlobeNewswire)
Nov-04-24 07:00AM	European Medicines Agency Confirms Acceptance of Marketing Authorization Application for AVT05, a Proposed Biosimilar to Simponi (golimumab) (GlobeNewswire)
Oct-30-24 08:30AM	Alvotech to Report Financial Results for the First Nine Months of 2024 on November 13, 2024, and Host Conference Call on November 14, 2024, at 8:00 am ET (GlobeNewswire)
Oct-25-24 08:00AM	Alvotech Meeting Investors and Presenting at the Jefferies 2024 London Healthcare Conference on November 19 20, 2024 (GlobeNewswire)
Oct-22-24 07:00AM	Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara (ustekinumab) (GlobeNewswire)
Oct-10-24 05:01AM	European Medicines Agency Confirms Acceptance of Marketing Application for AVT03, a Proposed Biosimilar to Prolia and Xgeva (GlobeNewswire)
Sep-25-24 05:01AM	Alvotech Initiates Confirmatory Patient Study for AVT16, a Proposed Biosimilar to Entyvio (GlobeNewswire)
Aug-26-24 09:15AM	Alvotech to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference (GlobeNewswire)
Aug-15-24 04:15PM	Alvotech Reports Record Revenues and Adjusted EBITDA for the Second Quarter and First Six Months of 2024 (GlobeNewswire) +7.96% +8.72%
04:30AM	European Medicines Agency Confirms Acceptance of Marketing Application for AVT06, a Proposed Biosimilar to Eylea (aflibercept) (GlobeNewswire)
Aug-01-24 04:02PM	Alvotech to Report Financial Results for the First Half of 2024 on August 15, 2024, and Host Conference Call on August 16, 2024, at 8:00 am ET (GlobeNewswire)
Jul-22-24 06:35AM	STADA and Alvotech launch Uzpruvo, the first approved ustekinumab biosimilar to Stelara, across Europe (GlobeNewswire)
Jul-11-24 04:45AM	Alvotech Announces Closing of Private Debt Financing (GlobeNewswire)
Jul-02-24 09:00AM	Alvotech Announces Positive Topline Results from Confirmatory Patient Study for AVT03, a Proposed Biosimilar for Prolia and Xgeva (GlobeNewswire)
Jul-01-24 05:35PM	Alvotech Issues New Shares to Holders of Convertible Bonds (GlobeNewswire)
05:10AM	Alvotech Announces Record Preliminary Results for Revenues and EBITDA for the Second Quarter of 2024 (GlobeNewswire)
Jun-26-24 04:50AM	Alvotech Receives Conversion Notices for Majority of Convertible Bonds (GlobeNewswire) -5.87%
Jun-25-24 09:40AM	Are Medical Stocks Lagging Alvotech (ALVO) This Year? (Zacks)
Jun-24-24 09:23AM	Here's Why You Should Consider Buying Alvotech (ALVO) Stock (Zacks)
Jun-22-24 09:03AM	Did Teva Pharmaceutical Industries Limited (TEVA)'s Pivot to Growth Strategy Help It Get a Positive Rating from Analysts? (Insider Monkey)
Jun-18-24 04:01AM	Alvotech and Advanz Pharma Sign Commercialization Agreement for Proposed Biosimilar to Eylea LD/HD in Europe (GlobeNewswire)
Jun-11-24 04:00AM	Alvotech and STADA add to Strategic Alliance through Denosumab Partnership (GlobeNewswire)
Jun-07-24 04:00AM	Alvotech Announces Strategic Refinancing Agreement (GlobeNewswire)
May-29-24 08:05AM	Alvotech to Participate in Jefferies Healthcare Conference in New York, June 5-6, 2024 (GlobeNewswire)
May-21-24 09:52PM	ALVO Stock Earnings: Alvotech Misses EPS for Q1 2024 (InvestorPlace)
05:15PM	Alvotech Reports Financial Results for First Quarter of 2024 and Provides a Business Update (GlobeNewswire)
10:05AM	Alvotech and Dr. Reddys Enter Into Collaboration for Commercialization of AVT03 (denosumab), a Biosimilar Candidate to Prolia & Xgeva in the U.S., Europe and UK (Business Wire)
07:55AM	Teva and Alvotech launch SIMLANDI in US for arthritis (Pharmaceutical Business Review)
May-20-24 08:25PM	Teva and Alvotech Announce SIMLANDI (adalimumab-ryvk) Injection Now Available in the U.S. (Business Wire)
May-15-24 09:30AM	Alvotech S.A. Annual General Meeting to be held June 7, 2024 (GlobeNewswire)
May-13-24 08:00AM	Alvotech Announces Webcast of First Quarter 2024 Financial Results on May 22, 2024, at 8:00 am EDT (12 noon GMT) (GlobeNewswire)
May-02-24 07:15AM	Alvotech Announces Participation at BofA Securities Healthcare Conference 2024 (GlobeNewswire)
Apr-30-24 04:00AM	U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira (adalimumab) (Business Wire)
Apr-24-24 04:00AM	Alvotech Announces Topline Results from a Confirmatory Clinical Study for AVT05, a Proposed Biosimilar for Simponi (golimumab) (GlobeNewswire)
Apr-19-24 06:10AM	Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira (adalimumab) (GlobeNewswire)
Apr-16-24 05:43PM	Alvotech and Teva Announce U.S. FDA Approval of SELARSDI (ustekinumab-aekn), biosimilar to Stelara (ustekinumab) (Business Wire)
Apr-03-24 07:41AM	Alvotech Hosts Audio Call for Investors at 8:15 am EDT on April 3, 2024 (GlobeNewswire)
Mar-22-24 04:15PM	Alvotech Announces Increase in Number of Own Shares (GlobeNewswire) -11.24%
Mar-20-24 09:52PM	ALVO Stock Earnings: Alvotech Reported Results for Q4 2023 (InvestorPlace)

Alvotech is a biotechnology company, which engages in the development and manufacture of biosimilar medicines. The firm is focusing on the development of its product candidates. It operates through the following geographical segments: Europe, North America, Asia, and Other. The company was founded by Robert Vilhelm Wessman in 2013 and is headquartered in Luxembourg.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Alvotech

Upgrade your FINVIZ experience